Piclamilast is primarily used in the field of medical research and pharmacology due to its role as a selective phosphodiesterase-4 (PDE4) inhibitor. It is studied for its potential anti-inflammatory properties, making it a candidate for treating inflammatory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and psoriasis. By inhibiting PDE4, it helps reduce the production of pro-inflammatory mediators and promotes the release of anti-inflammatory substances, which can alleviate symptoms associated with these conditions. Additionally, Piclamilast has been explored for its potential in treating neurodegenerative diseases like Alzheimer’s, as inflammation plays a key role in their progression. Its application in clinical trials continues to assess its efficacy and safety for therapeutic use.